NOW AVAILABLE
The next generation in online publishing...

Sign up to read the digital versions of Managed Care, P&T, and Biotechnology Healthcare. These digital editions are free, searchable, and can be downloaded and read offline. To read a sample of the digital version of Managed Care, follow this link:

Sample digital edition

Register for a free digital subscription

Archive issues of Managed Care:

• January 2008
• February 2008
• March 2008
• April 2008
• May 2008
• June 2008

MANAGED CARE May 2007. ©MediMedia USA

The Appropriate Omalizumab Patient

Management of the uncontrolled asthma patient and case examples

Jill Karpel, MD, Donald A. Bukstein, MD,* Robert LoNigro, MD†

Beth Thalheim Asthma Center, North Shore University Hospital, Manhasset, N.Y.; *Family Medicine at University of Wisconsin–Madison; †Tufts Health Plan, Boston, Mass.

• Full text in PDF

Abstract

Allergy is a significant component in many asthma patients. Omalizumab is a monoclonal anti–immunoglobulin E antibody for the treatment of allergic asthma. Clinical trials have shown that omalizumab treatment is associated with improved symptom control and reduced inhaled corticosteroid doses, resulting in fewer exacerbations and reduced utilization of resources. Omalizumab therapy may benefit patients who remain uncontrolled or who cannot tolerate standard therapy.

Key words: adult, asthma, immunoglobulin E, monoclonal antibody, prior authorization

Corresponding author:

Jill Karpel, MD
Mailing Address:
410 Lakeville Road, Suite 107
New Hyde Park, N.Y. 11040
Fax: 516 465-5454